Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

An anti-respiratory syncytial virus drug for patients with cardiovascular disease

A syncytial virus and anti-respiratory technology, applied in the field of medicine, can solve problems such as the inability to use ribavirin and myocardial damage, and achieve the effects of easy production and promotion, enhanced inhibitory effect, and strong practicability

Active Publication Date: 2020-06-30
SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ribavirin has the effect of inhibiting respiratory syncytial virus (RSV), influenza virus and other viruses in vitro, and also has immune effect on RSV in vivo, but taking ribavirin can cause myocardial damage, so it has cardiac Ribavirin should not be used in patients with medical history or obvious symptoms of heart disease (Ivey KS et al. J Am Coll Cardiol, 2018, 71(14):1574; Yang Congde et al., Journal of Clinical Military Medicine, 2016,44(10):1099)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An anti-respiratory syncytial virus drug for patients with cardiovascular disease
  • An anti-respiratory syncytial virus drug for patients with cardiovascular disease
  • An anti-respiratory syncytial virus drug for patients with cardiovascular disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Derivative Preparation

[0028] In a single-necked bottle, mix substituted phenylacetic acid (0.01mol), substituted benzaldehyde (0.01mol), acetic anhydride 6.0mL (freshly distilled) and triethylamine 0.7mL (freshly distilled), and heat Reflux reaction in the bag for 4 to 6 hours, lower the temperature to 100°C, add 1 to 2 mL of distilled water to decompose, and then stir for 5 minutes, remove the reactant from the electric heating bag, cool to room temperature, put it into 60 mL of water, leave it at room temperature to precipitate solids, and filter The product was obtained as a solid.

[0029] For the solid product in the previous step, if adding NaOH solution, adjust the pH at about 12, stir and react at 90°C for 2 hours, cool to room temperature, adjust the pH at 6-7 with dilute HCl solution, precipitate off-white solid, and filter to obtain the product , E-configuration derivatives A1, A4, A5 and A6 with phenolic hydroxyl groups can be prepared. The pr...

Embodiment 2

[0042] Embodiment 2 Biological test

[0043] 1. Screening for antiviral activity

[0044] In vitro antiviral effect of ferulic acid derivatives, common respiratory syncytial virus (RSV), herpes simplex virus type 1 (HSV-1), enterovirus type 71 (EV71) and other antiviral effect research, reference ( Yue Lulu et al., World Traditional Chinese Medicine, 2018, 13(01):199-206) method, observing the cell survival rate under a microscope. The content of this part is tested by Shandong Provincial Antiviral Research Center.

[0045] Ferulic acid (FA) and its derivatives (A1-A6) were prepared into the test solution. The experiment was divided into a cell control group, a virus control group and a drug group, and ribavirin was used as a reference. Three replicate wells were set up for each group. In the drug group, ferulic acid derivatives were diluted with cell maintenance solution, and serially diluted from 1:2, and added to the cultured monolayer human laryngeal carcinoma cells (H...

Embodiment 3

[0065] Embodiment 3 pharmaceutical composition preparation

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicine and relates to the application of an antiviral drug suitable for cardiovascular disease patients. Ferulic acid derivative have selective inhibitory effect on respiratory syncytial virus (RSV) and proliferation and protective effect on human umbilical vein endothelial cells (HUVEC), and can be use for preparing antiviral drugs for patients with cardiovascular disease symptom.

Description

technical field [0001] The invention relates to the application of a ferulic acid derivative in the preparation of antiviral drugs, especially the application in the preparation of anti-respiratory syncytial virus drugs, belonging to the technical field of medicine. Background technique [0002] The common pathogens causing respiratory infection in hospitalized patients include respiratory syncytial virus, etc. Children with congenital heart disease have poor resistance and are susceptible to respiratory syncytial virus. However, in pediatric drug prescriptions, ribavirin is abused More serious (Li Qing et al., Chinese Journal of Hospital Infection, 2015,25(18):4260). Ribavirin has the effect of inhibiting respiratory syncytial virus (RSV), influenza virus and other viruses in vitro, and also has immune effect on RSV in vivo, but taking ribavirin can cause myocardial damage, so it has cardiac Ribavirin should not be used in patients with medical history or obvious symptoms ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/222A61P31/14A61P31/16A61P31/22
CPCA61K31/222A61P31/14A61P31/16A61P31/22
Inventor 毛近隆闫滨管西芹高世杰王集会张欣欣张瑞王丹丹
Owner SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com